Securities code: 002086 securities abbreviation: St Toyo Announcement No.: 2022-020 Shandong Oriental Ocean Sci-Tech Co.Ltd(002086)
Stock trading abnormal fluctuation announcement
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without false records, misleading statements or major omissions.
1、 Introduction to abnormal fluctuations in stock trading
Shandong Oriental Ocean Sci-Tech Co.Ltd(002086) (securities code: 002086, securities abbreviation: St Toyo, hereinafter referred to as the “company”) the cumulative decline deviation of the closing price of the stock for three consecutive trading days (January 17, 2022, January 18, 2022 and January 19, 2022) exceeded 12%. According to the provisions of the Listing Rules of Shenzhen Stock Exchange, it belongs to abnormal fluctuations in stock trading.
2、 Description of the company’s concern and verification
In view of the abnormal fluctuation of the company’s stock trading, the board of directors of the company verified the controlling shareholders, actual controllers, shareholders holding more than 5%, all directors, supervisors and senior managers of the company through telephone and on-site inquiry:
1. The company does not find any information disclosed in the previous period that needs to be corrected or supplemented;
2. The company has not found any unpublished material information that may or has had a great impact on the company’s stock trading price reported by the public media recently;
3. The company’s current business situation and internal and external business environment have not changed significantly;
4. After verification, the controlling shareholders and actual controllers of the company did not buy or sell the company’s shares during the abnormal fluctuation of stock trading;
5. The company disclosed the performance forecast for 2021 (Announcement No.: 2022-017) on January 19, 2022. The net profit loss attributable to the shareholders of the listed company in 2021 was 200 million yuan – 260 million yuan, and the net profit loss after deducting non recurring profits and losses was 161.17 million yuan – 221.17 million yuan. The relevant data of the performance forecast were the preliminary calculation results of the company’s financial department, It has not been audited by an accounting firm. The company has made pre communication with the accounting firm on major matters related to the performance forecast, and there is no major difference between the two sides.
6. The company does not violate fair information disclosure.
3、 Whether there is a description of the information that should be disclosed but not disclosed
The board of directors of the company confirms that the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the relevant provisions of the Listing Rules of Shenzhen Stock Exchange; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions and has a great impact on the trading price of the company’s shares and their derivatives; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips
1. Through self inspection, the company does not violate fair information disclosure.
2. Up to now, matters related to the occupation of funds by the company’s controlling shareholders and illegal guarantee have not been resolved. The balance of funds occupied by the controlling shareholders was 1184989402.51 yuan (Unaudited), accounting for 82.79% of the company’s latest audited net assets, and the balance of illegal guarantees that failed to perform relevant review procedures was 785974023.62 yuan, accounting for 54.92% of the company’s latest audited net assets. Please make prudent decisions and pay attention to investment risks, For specific progress, please pay attention to the risk progress announcement issued by the company every month.
3. Recently, several investors have repeatedly asked questions about the production and sales of covid-19 test kits of avico Biotechnology Co., Ltd., a subsidiary of the company, on the interactive platform. Covid-19 test kits of avico Biotechnology Co., Ltd., a subsidiary of the company, are currently produced according to orders. The actual sales situation is affected by many factors and there is uncertainty, At present, it is impossible to estimate the performance changes that the product may bring to the company. Please pay attention to the relevant periodic reports for specific sales data. At present, the company’s independently developed Helicobacter pylori related detection reagent products have only completed clinical trials and have not submitted an application for registration and approval in China. Please pay attention to investment risks and invest rationally.
4. The information disclosure media designated by the company are securities times, Shanghai Securities News, China Securities News, securities daily and http://www.cn.info.com.cn, All information of the company shall be subject to the information published in the above designated media. Please make careful decisions and pay attention to investment risks. It is hereby announced.
Shandong Oriental Ocean Sci-Tech Co.Ltd(002086) board of directors
January 20, 2002
